Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shinya Hiramitsu

Showing results (51-60 of 59) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 59 results.
Rheumatology (Oxford, England)|October 4, 2021
Optimal uric acid levels by febuxostat treatment and cerebral, cardiorenovascular risks: post hoc analysis of a randomized controlled trialSunao Kojima, Kazuaki Uchiyama, Naoto Yokota, et al.
Clinical and Experimental Hypertension (New York, N.Y. : 1993)|October 30, 2013
Febuxostat (Feburic tablet) in the management of hyperuricemia in a general practice cohort of Japanese patients with a high prevalence of cardiovascular problemsShinya Hiramitsu, Yoshiaki Ishiguro, Hiroyuki Matsuyama, et al.
Clinical Pharmacology and Therapeutics|February 23, 2024
Impacts of Febuxostat on Cerebral and Cardiovascular Events in Elderly Patients with Hyperuricemia: Post Hoc Analysis of a Randomized Controlled TrialMasahiro Sugawara, Sunao Kojima, Ichiro Hisatome, et al.
Cardiovascular Drugs and Therapy|June 1, 2022
C-reactive Protein Levels and Cardiovascular Outcomes After Febuxostat Treatment in Patients with Asymptomatic Hyperuricemia: Post-hoc Analysis of a Randomized Controlled StudySunao Kojima, Kazuaki Uchiyama, Naoto Yokota, et al.
International Journal of Cardiology|December 5, 2021
Effect of febuxostat on clinical outcomes in patients with hyperuricemia and cardiovascular diseaseMasaaki Konishi, Sunao Kojima, Kazuaki Uchiyama, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|February 7, 2023
Febuxostat and renal outcomes: post-hoc analysis of a randomized trialKentaro Kohagura, Sunao Kojima, Kazuaki Uchiyama, et al.
Cardiovascular Drugs and Therapy|July 6, 2018
Rationale and Design of the Multicenter Trial on Japan Working Group on the Effects of Angiotensin Receptor Blockers Selection (Azilsartan vs. Candesartan) on Diastolic Function in the Patients Suffering from Heart Failure with Preserved Ejection Fraction: J-TASTE TrialHiroyuki Takahama, Masanori Asakura, Yukio Abe, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|March 12, 2025
Investigation of the Effect of Empagliflozin on Cardiac Sympathetic and Parasympathetic Nerve Activity Analyzed From Heart Rate Variability Frequency in Japanese Patients With Type 2 Diabetes　- Results From the EMPYREAN StudyHirohiko Motoki, Izuru Masuda, Koji Oba, et al.
Scientific Reports|August 2, 2023
Efficacy of azilsartan on left ventricular diastolic dysfunction compared with candesartan: J-TASTE randomized controlled trialShin Ito, Hiroyuki Takahama, Masanori Asakura, et al.
Pageof 6

Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
Rheumatology (Oxford, England)|October 4, 2021
Optimal uric acid levels by febuxostat treatment and cerebral, cardiorenovascular risks: post hoc analysis of a randomized controlled trialSunao Kojima, Kazuaki Uchiyama, Naoto Yokota, et al.
Clinical and Experimental Hypertension (New York, N.Y. : 1993)|October 30, 2013
Febuxostat (Feburic tablet) in the management of hyperuricemia in a general practice cohort of Japanese patients with a high prevalence of cardiovascular problemsShinya Hiramitsu, Yoshiaki Ishiguro, Hiroyuki Matsuyama, et al.
Clinical Pharmacology and Therapeutics|February 23, 2024
Impacts of Febuxostat on Cerebral and Cardiovascular Events in Elderly Patients with Hyperuricemia: Post Hoc Analysis of a Randomized Controlled TrialMasahiro Sugawara, Sunao Kojima, Ichiro Hisatome, et al.
Cardiovascular Drugs and Therapy|June 1, 2022
C-reactive Protein Levels and Cardiovascular Outcomes After Febuxostat Treatment in Patients with Asymptomatic Hyperuricemia: Post-hoc Analysis of a Randomized Controlled StudySunao Kojima, Kazuaki Uchiyama, Naoto Yokota, et al.
International Journal of Cardiology|December 5, 2021
Effect of febuxostat on clinical outcomes in patients with hyperuricemia and cardiovascular diseaseMasaaki Konishi, Sunao Kojima, Kazuaki Uchiyama, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|February 7, 2023
Febuxostat and renal outcomes: post-hoc analysis of a randomized trialKentaro Kohagura, Sunao Kojima, Kazuaki Uchiyama, et al.
Cardiovascular Drugs and Therapy|July 6, 2018
Rationale and Design of the Multicenter Trial on Japan Working Group on the Effects of Angiotensin Receptor Blockers Selection (Azilsartan vs. Candesartan) on Diastolic Function in the Patients Suffering from Heart Failure with Preserved Ejection Fraction: J-TASTE TrialHiroyuki Takahama, Masanori Asakura, Yukio Abe, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|March 12, 2025
Investigation of the Effect of Empagliflozin on Cardiac Sympathetic and Parasympathetic Nerve Activity Analyzed From Heart Rate Variability Frequency in Japanese Patients With Type 2 Diabetes　- Results From the EMPYREAN StudyHirohiko Motoki, Izuru Masuda, Koji Oba, et al.
Scientific Reports|August 2, 2023
Efficacy of azilsartan on left ventricular diastolic dysfunction compared with candesartan: J-TASTE randomized controlled trialShin Ito, Hiroyuki Takahama, Masanori Asakura, et al.
Pageof 6